A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Herbert Aaron Eradat
Research Funding - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Kanti Roop Rai
Research Funding - Gilead Sciences
Charles Michael Farber
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Jan Andrzej Walewski
No relevant relationships to disclose
Zwi N. Berneman
Research Funding - Gilead Sciences
Susan Mary O'Brien
Research Funding - Gilead Sciences
Jennifer R. Brown
No relevant relationships to disclose
Sissy Peterman
Employment or Leadership Position - Gilead Sciences
Research Funding - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Paula Cramer
Research Funding - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences